◆英語タイトル:Basilea Pharmaceutica Ltd (BSLN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH61547FSA
◆発行会社(調査会社):
GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Basilea Pharmaceutica Ltd (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company’s products address increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections and fungal infections. Basilea also conducts research in the areas of anti-infectives, cancer and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology, and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy and Denmark. Basilea is headquartered in Basel, Switzerland.
Basilea Pharmaceutica Ltd Key Recent Developments
Apr 01,2021: Basilea announces closing of previously announced transaction regarding divestment of its Chinese R&D subsidiary
Mar 24,2021: Basilea reports positive interim results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene mutation- or amplification-positive patients with bile duct cancer (iCCA)
Feb 16,2021: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
Feb 12,2021: Basilea präsentiert auf ASCO GU Symposium Dosisfindungs-Ergebnisse für Derazantinib/PD-L1-Checkpoint-Inhibitor-Kombination aus FIDES-02-Studie für Patienten mit soliden Tumoren
Feb 11,2021: Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor
This comprehensive SWOT profile of Basilea Pharmaceutica Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Basilea Pharmaceutica Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).
The profile contains critical company information including*,
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 – About the Company
Basilea Pharmaceutica Ltd – Key Information
Basilea Pharmaceutica Ltd – Overview
Basilea Pharmaceutica Ltd – Key Employees
Basilea Pharmaceutica Ltd – Key Employee Biographies
Basilea Pharmaceutica Ltd – Key Operational Heads
Basilea Pharmaceutica Ltd – Major Products and Services
Basilea Pharmaceutica Ltd – History
Basilea Pharmaceutica Ltd – Company Statement
Basilea Pharmaceutica Ltd – Locations And Subsidiaries
Basilea Pharmaceutica Ltd
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Basilea Pharmaceutica Ltd – Business Description
Basilea Pharmaceutica Ltd – Corporate Strategy
Basilea Pharmaceutica Ltd – SWOT Analysis
SWOT Analysis – Overview
Basilea Pharmaceutica Ltd – Strengths
Basilea Pharmaceutica Ltd – Weaknesses
Basilea Pharmaceutica Ltd – Opportunities
Basilea Pharmaceutica Ltd – Threats
Basilea Pharmaceutica Ltd – Key Competitors
Section 3 – Company Financial Performance Charts
Basilea Pharmaceutica Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Appendix
Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Note*: Some sections may be missing if data is unavailable for the company
List of Tables
Basilea Pharmaceutica Ltd, Key Information
Basilea Pharmaceutica Ltd, Key Ratios
Basilea Pharmaceutica Ltd, Share Data
Basilea Pharmaceutica Ltd, Major Products and Services
Basilea Pharmaceutica Ltd, History
Basilea Pharmaceutica Ltd, Key Employees
Basilea Pharmaceutica Ltd, Key Employee Biographies
Basilea Pharmaceutica Ltd, Key Operational Heads
Basilea Pharmaceutica Ltd, Other Locations
Basilea Pharmaceutica Ltd, Subsidiaries
Basilea Pharmaceutica Ltd, Key Competitors
Basilea Pharmaceutica Ltd, SWOT Analysis
Basilea Pharmaceutica Ltd, Ratios based on current share price
Basilea Pharmaceutica Ltd, Annual Ratios
Basilea Pharmaceutica Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios